Last update 21 Mar 2024
MUCL1
mucin like 1
Last update 21 Mar 2024
Basic Info
Synonyms mucin like 1, Mucin-like protein 1, MUCL1 + [3] |
Introduction May play a role as marker for the diagnosis of metastatic breast cancer. |
Related
100 Clinical Results associated with MUCL1
Login to view more data
100 Translational Medicine associated with MUCL1
Login to view more data
0 Patents (Medical) associated with MUCL1
Login to view more data
72
Literatures (Medical) associated with MUCL129 Aug 2023·Molecular and biochemical parasitology
Characterization of the major surface glycoconjugates of Trypanosoma theileri.
Article
Author: Rupa Nagar ; Isobel Hambleton ; Michele Tinti ; Mark Carrington ; Michael A J Ferguson
Trypanosoma theileri maintains a long-term extracellular infection with a low parasitaemia in bovids. The surface of this parasite is predicted to be decorated with several surface molecules including membrane surface proteases (MSPs), trans-sialidases and T. theileri putative surface proteins (TTPSPs). However, there are no experimental data to verify this hypothesis. Here, we have purified and partially characterized the surface glycoconjugates of T. theileri using biochemical and mass spectrometry-based approaches. The glycoconjugates fall into two classes: glycoproteins and glycolipids. Proteomic analysis of the glycoprotein fraction demonstrated the presence of MSPs and abundant mucin-like TTPSPs, with most predicted to be GPI-anchored. Mass spectrometric characterization of the glycolipid fraction showed that these are mannose- and galactose-containing glycoinositolphospholipids (GIPLs) that are larger and more diverse than those of its phylogenetic relative T. cruzi, containing up to 10 hexose residues and carrying either alkylacyl-phosphatidylinositol or inositol-phospho-ceramide (IPC) lipid components.
20 Jul 2023·Aging
miRNA-186-5p inhibits migration, invasion and proliferation of breast cancer cells by targeting SBEM.
Article
Author: Hui Hao ; Bingsheng Wang ; Lin Yang ; Yinzhou Sang ; Wei Xu ; Wei Liu ; Lili Zhang ; Da Jiang
The paper aimed to investigate the effect of miR186-5p on invasion and migration of breast cancer cells and its molecular mechanism. MicroRNA-186-5p was found to be low expressed in breast cancer and highly expressed in SBEM by bioinformatics analysis. After transfecting MDA-MB-231 cells with miR-186-5p inhibitor NC, miR-186-5p inhibitor, miR-186-5p mimic NC and miR-186-5p mimic, respectively. The migration and invasive ability of breast cancer cells were detected by cell scratch test and Transwell test. Moreover, after adding 740 Y-P to the miR-186-5p mimic NC group and miR-186-5p mimic group cells, SBEM and PI3K pathway-related proteins were detected by Western blotting and proliferation of the cancer cells was evaluated by monoclonal cell experiment. Meanwhile, exogenous miR-186-5p mimic in MDA-MB-231 cells significantly inhibited the expression of SBEM, p-PI3K, p-AKT and their downstream pathways, MMP1, MMP3, MMP9, CyclinD1, PCNA and CyclinB1 proteins and reduced proliferation of breast cancer cells. Furthermore, the expression of SBEM protein in the miR-186-5p mimic + 740Y-P group was significantly lower than the miR-186-5p mimic NC + 740Y-P group after adding 740 Y-P. However, there were no significant changes in the protein's levels associated with PI3K pathway and the cancer cells proliferation. These results suggest that low expression of miR-186-5p in breast cancer results in an abnormally high expression of SBEM, activation of PI3K/AKT signaling pathway, promoting migration and invasion of human breast cancer cells.
04 Jan 2023·Cellular oncology (Dordrecht)
The Breast Cancer Single-Cell Atlas: Defining cellular heterogeneity within model cell lines and primary tumors to inform disease subtype, stemness, and treatment options.
Article
Author: Arpit Dave ; Daniel Charytonowicz ; Nancy J Francoeur ; Michael Beaumont ; Kristin Beaumont ; Hank Schmidt ; Tizita Zeleke ; Jose Silva ; Robert Sebra
PURPOSE:
Breast Cancer (BC) is the most diagnosed cancer in women; however, through significant research, relative survival rates have significantly improved. Despite progress, there remains a gap in our understanding of BC subtypes and personalized treatments. This manuscript characterized cellular heterogeneity in BC cell lines through scRNAseq to resolve variability in subtyping, disease modeling potential, and therapeutic targeting predictions.
METHODS:
We generated a Breast Cancer Single-Cell Cell Line Atlas (BSCLA) to help inform future BC research. We sequenced over 36,195 cells composed of 13 cell lines spanning the spectrum of clinical BC subtypes and leveraged publicly available data comprising 39,214 cells from 26 primary tumors.
RESULTS:
Unsupervised clustering identified 49 subpopulations within the cell line dataset. We resolve ambiguity in subtype annotation comparing expression of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 genes. Gene correlations with disease subtype highlighted S100A7 and MUCL1 overexpression in HER2 + cells as possible cell motility and localization drivers. We also present genes driving populational drifts to generate novel gene vectors characterizing each subpopulation. A global Cancer Stem Cell (CSC) scoring vector was used to identify stemness potential for subpopulations and model multi-potency. Finally, we overlay the BSCLA dataset with FDA-approved targets to identify to predict the efficacy of subpopulation-specific therapies.
CONCLUSION:
The BSCLA defines the heterogeneity within BC cell lines, enhancing our overall understanding of BC cellular diversity to guide future BC research, including model cell line selection, unintended sample source effects, stemness factors between cell lines, and cell type-specific treatment response.
1
News (Medical) associated with MUCL103 Nov 2023
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 03 November, 2023 – Glycotope GmbH, a biotechnology company with a proprietary platform technology for developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present a poster on antibodies that specifically recognize cancer-associated glycoforms of mucin-like proteins at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting, being held in San Diego, California, United States, between 1-5 November 2023. Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: “Our platform technology is suitable to target protein/carbohydrate combined epitopes with specific antibodies. We successfully generated two antibodies which target distinct, tumor-specific epitopes on two mucin-like proteins, respectively, comprising a tumor-associated glycan in combination with the specific target protein. Due to this glycan dependency, our antibodies show markedly decreased off-tumor binding which may improve safety for highly potent therapeutic approaches like ADCs, CARs or radiopharmaceutics. We are looking forward to presenting our work at the SITC Annual Meeting 2023 and discussing our approach with leading cancer research experts.” Poster details are as follows: Abstract: Available here Download: Available on Nov 3, 9:00 AM PDT - here Title: Antibodies specifically recognizing cancer-associated glycoforms of mucin-like proteins Abstract Number: 1462 Session Date and Time: Saturday Nov 4, 2023 9:00 AM - 8:30 PM Location: Exhibition Hall A Contact Information: Glycotope GmbH Dr. Patrik Kehler (CSO) Phone: +49 30 9489 2600 Email: contact@glycotope.com About Glycotope Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Glycotope has to date discovered in excess of 200 GlycoTargets with antibodies against several of these targets currently under development. Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins. Visit www.glycotope.com
Immunotherapy
Analysis
Perform a panoramic analysis of this field.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free